Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective
Abstract GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014. Over time, data from secondary and exploratory objectives of large randomized controlled-t...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Nefrologia
2024-11-01
|
| Series: | Brazilian Journal of Nephrology |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002024000400405&lng=en&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850194261144764416 |
|---|---|
| author | Jorge Rico-Fontalvo Maricely Reina María José Soler Mario Unigarro-Palacios Juan Pablo Castañeda-González Javier Jiménez Quintero María Raad-Sarabia Thyago Proença de Moraes Rodrigo Daza-Arnedo |
| author_facet | Jorge Rico-Fontalvo Maricely Reina María José Soler Mario Unigarro-Palacios Juan Pablo Castañeda-González Javier Jiménez Quintero María Raad-Sarabia Thyago Proença de Moraes Rodrigo Daza-Arnedo |
| author_sort | Jorge Rico-Fontalvo |
| collection | DOAJ |
| description | Abstract GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014. Over time, data from secondary and exploratory objectives of large randomized controlled-trials suggested that GLP1-RAs could also exert renal action by slowing the progression of kidney disease in patients with and without diabetes. Based on this rationale, the Flow study (1 mg semaglutide vs placebo) was designed and recruitment began in 2019 until May 2021. The recently published results confirmed the effect of semaglutide in reducing the composite renal outcome. However, similar to SGLT2 inhibitors, the potential mechanisms behind the renal effects of GLP1-RAs still need to be elucidated. The aim of this review is to address the different physiological mechanisms of GLP1-RAs at the renal level, using evidence from experimental studies and current scientific literature. |
| format | Article |
| id | doaj-art-4bc7bb9bde434fb9b3b9de965eafed79 |
| institution | OA Journals |
| issn | 2175-8239 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Sociedade Brasileira de Nefrologia |
| record_format | Article |
| series | Brazilian Journal of Nephrology |
| spelling | doaj-art-4bc7bb9bde434fb9b3b9de965eafed792025-08-20T02:14:02ZengSociedade Brasileira de NefrologiaBrazilian Journal of Nephrology2175-82392024-11-0146410.1590/2175-8239-jbn-2024-0101enKidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspectiveJorge Rico-Fontalvohttps://orcid.org/0000-0002-2852-1241Maricely Reinahttps://orcid.org/0000-0002-1262-1555María José Solerhttps://orcid.org/0000-0003-3621-0766Mario Unigarro-Palacioshttps://orcid.org/0000-0002-7753-6079Juan Pablo Castañeda-Gonzálezhttps://orcid.org/0000-0001-5400-9068Javier Jiménez Quinterohttps://orcid.org/0009-0007-5150-7580María Raad-Sarabiahttps://orcid.org/0000-0002-7080-7024Thyago Proença de Moraeshttps://orcid.org/0000-0002-2983-3968Rodrigo Daza-Arnedohttps://orcid.org/0000-0002-6295-4972Abstract GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014. Over time, data from secondary and exploratory objectives of large randomized controlled-trials suggested that GLP1-RAs could also exert renal action by slowing the progression of kidney disease in patients with and without diabetes. Based on this rationale, the Flow study (1 mg semaglutide vs placebo) was designed and recruitment began in 2019 until May 2021. The recently published results confirmed the effect of semaglutide in reducing the composite renal outcome. However, similar to SGLT2 inhibitors, the potential mechanisms behind the renal effects of GLP1-RAs still need to be elucidated. The aim of this review is to address the different physiological mechanisms of GLP1-RAs at the renal level, using evidence from experimental studies and current scientific literature.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002024000400405&lng=en&tlng=enAlbuminuriaDiabetesIncretinsObesityKidney disease |
| spellingShingle | Jorge Rico-Fontalvo Maricely Reina María José Soler Mario Unigarro-Palacios Juan Pablo Castañeda-González Javier Jiménez Quintero María Raad-Sarabia Thyago Proença de Moraes Rodrigo Daza-Arnedo Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective Brazilian Journal of Nephrology Albuminuria Diabetes Incretins Obesity Kidney disease |
| title | Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective |
| title_full | Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective |
| title_fullStr | Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective |
| title_full_unstemmed | Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective |
| title_short | Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective |
| title_sort | kidney effects of glucagon like peptide 1 glp1 from molecular foundations to a pharmacophysiological perspective |
| topic | Albuminuria Diabetes Incretins Obesity Kidney disease |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002024000400405&lng=en&tlng=en |
| work_keys_str_mv | AT jorgericofontalvo kidneyeffectsofglucagonlikepeptide1glp1frommolecularfoundationstoapharmacophysiologicalperspective AT maricelyreina kidneyeffectsofglucagonlikepeptide1glp1frommolecularfoundationstoapharmacophysiologicalperspective AT mariajosesoler kidneyeffectsofglucagonlikepeptide1glp1frommolecularfoundationstoapharmacophysiologicalperspective AT mariounigarropalacios kidneyeffectsofglucagonlikepeptide1glp1frommolecularfoundationstoapharmacophysiologicalperspective AT juanpablocastanedagonzalez kidneyeffectsofglucagonlikepeptide1glp1frommolecularfoundationstoapharmacophysiologicalperspective AT javierjimenezquintero kidneyeffectsofglucagonlikepeptide1glp1frommolecularfoundationstoapharmacophysiologicalperspective AT mariaraadsarabia kidneyeffectsofglucagonlikepeptide1glp1frommolecularfoundationstoapharmacophysiologicalperspective AT thyagoproencademoraes kidneyeffectsofglucagonlikepeptide1glp1frommolecularfoundationstoapharmacophysiologicalperspective AT rodrigodazaarnedo kidneyeffectsofglucagonlikepeptide1glp1frommolecularfoundationstoapharmacophysiologicalperspective |